onlinepharmacy

0 مشاهدات
2 يقومون بالنقاش
000000000x
·
--
مقالة
عرض الترجمة
JD Health: GS Keeps Buy After the 15% Drop — Target Cut to HK$51JD Health: GS Keeps Buy After the 15% Drop — Target Cut to HK$51 $6618.HK GOLDMAN SACHS | LINCOLN KONG, RONALD KEUNG, LUQING ZHOU • 19 November 2026 1. Why did JD Health fall 15% — and why does Goldman Sachs call it overdone? • Shares fell 15% on results day (19 November) after softer 4Q26 topline guidance — now double-digit % year over year — and worries about the 2027 growth outlook. • Goldman Sachs calls the correction overdone: JD Health can still deliver low-teen % sales growth amid macro weakness and keep gaining share. • Margin expansion stays intact on scale benefits and supply-chain management, with 20% core operating profit growth into 2027 after a 30% increase in 2026. • The stock trades at 12x 2027E P/E, a historical low — ex-cash, just 3–4x forward P/E. 2. What actually happened in 3Q26 — revenue in line, profit a miss? • Revenue rose 17% year over year, in line with expectations; adjusted operating profit rose 14% year over year, but 11% below Goldman Sachs' estimate. • Adjusted operating margin slipped 0.1 percentage points year over year on front-loaded sales and marketing spending. • By category: drugs grew 30%+ year over year, medical devices at a mid-single-digit % pace, nutrition at a high-single-digit % pace. • Gross margin kept expanding on procurement scale and advertising monetization, despite ongoing price competition. 3. Why is 4Q26 set to slow — nutrition, flu, or both? • Management guides 4Q26 revenue growth at double-digit % year over year: drugs 20–25%, medical devices mid-single-digit %, nutrition low-single-digit %. • Nutrition weakened again in 4Q26 after news flow around leading brands dented consumer confidence; management calls it temporary and still sees share gains in the category. • The flu season is materially weaker than in 4Q25 — flu periods also drive platform traffic and chronic-disease demand, not just flu-drug sales. • Growth is expected to re-accelerate from 1Q27 as nutrition recovers and drug momentum holds. 4. What changed in the forecasts — and what should investors watch? • The 12-month target price was cut to HK$51 from HK$59; the target multiple fell to 18x (from 22x) on slower topline growth and peer de-rating. Buy is kept. • 2026E–28E revenue estimates were cut 2–4%; net profit estimates cut 2–6%. • FY26 profit guidance is unchanged: non-IFRS operating profit +30% year over year; 2027 profit growth is expected to outpace revenue growth. • Watch next: the buyback continues and dividends are increasingly likely, with Hong Kong tax residency secured; risks are slower 2027 sales, margin pressure from delivery, offline and AI investment, and competition from online pharmacy, O2O and livestreaming e-commerce. #JDHealth #OnlinePharmacy #ChinaStocks #Healthcare #Ecommerce Source: Goldman Sachs, 19 November 2026. Based solely on the report provided; forecasts are not guaranteed. For reference only; not investment advice. Read the full breakdown on Unhidea: https://unhidea.com/en/articles/research-50fbe9820c7c4f99964198039c666fb8-en Visit unhidea.com for more of the latest sell-side research interpretations.

JD Health: GS Keeps Buy After the 15% Drop — Target Cut to HK$51

JD Health: GS Keeps Buy After the 15% Drop — Target Cut to HK$51
$6618.HK
GOLDMAN SACHS | LINCOLN KONG, RONALD KEUNG, LUQING ZHOU • 19 November 2026
1. Why did JD Health fall 15% — and why does Goldman Sachs call it overdone?
• Shares fell 15% on results day (19 November) after softer 4Q26 topline guidance — now double-digit % year over year — and worries about the 2027 growth outlook.
• Goldman Sachs calls the correction overdone: JD Health can still deliver low-teen % sales growth amid macro weakness and keep gaining share.
• Margin expansion stays intact on scale benefits and supply-chain management, with 20% core operating profit growth into 2027 after a 30% increase in 2026.
• The stock trades at 12x 2027E P/E, a historical low — ex-cash, just 3–4x forward P/E.
2. What actually happened in 3Q26 — revenue in line, profit a miss?
• Revenue rose 17% year over year, in line with expectations; adjusted operating profit rose 14% year over year, but 11% below Goldman Sachs' estimate.
• Adjusted operating margin slipped 0.1 percentage points year over year on front-loaded sales and marketing spending.
• By category: drugs grew 30%+ year over year, medical devices at a mid-single-digit % pace, nutrition at a high-single-digit % pace.
• Gross margin kept expanding on procurement scale and advertising monetization, despite ongoing price competition.
3. Why is 4Q26 set to slow — nutrition, flu, or both?
• Management guides 4Q26 revenue growth at double-digit % year over year: drugs 20–25%, medical devices mid-single-digit %, nutrition low-single-digit %.
• Nutrition weakened again in 4Q26 after news flow around leading brands dented consumer confidence; management calls it temporary and still sees share gains in the category.
• The flu season is materially weaker than in 4Q25 — flu periods also drive platform traffic and chronic-disease demand, not just flu-drug sales.
• Growth is expected to re-accelerate from 1Q27 as nutrition recovers and drug momentum holds.
4. What changed in the forecasts — and what should investors watch?
• The 12-month target price was cut to HK$51 from HK$59; the target multiple fell to 18x (from 22x) on slower topline growth and peer de-rating. Buy is kept.
• 2026E–28E revenue estimates were cut 2–4%; net profit estimates cut 2–6%.
• FY26 profit guidance is unchanged: non-IFRS operating profit +30% year over year; 2027 profit growth is expected to outpace revenue growth.
• Watch next: the buyback continues and dividends are increasingly likely, with Hong Kong tax residency secured; risks are slower 2027 sales, margin pressure from delivery, offline and AI investment, and competition from online pharmacy, O2O and livestreaming e-commerce.
#JDHealth #OnlinePharmacy #ChinaStocks #Healthcare #Ecommerce
Source: Goldman Sachs, 19 November 2026. Based solely on the report provided; forecasts are not guaranteed. For reference only; not investment advice.
Read the full breakdown on Unhidea: https://unhidea.com/en/articles/research-50fbe9820c7c4f99964198039c666fb8-en
Visit unhidea.com for more of the latest sell-side research interpretations.
JDUS‎-2.29%
سجّل الدخول لاستكشاف المزيد من المُحتوى
انضم إلى مُستخدمي العملات الرقمية حول العالم على Binance Square
⚡️ احصل على أحدث المعلومات المفيدة عن العملات الرقمية.
💬 موثوقة من قبل أكبر منصّة لتداول العملات الرقمية في العالم.
👍 اكتشف الرؤى الحقيقية من صنّاع المُحتوى الموثوقين.
البريد الإلكتروني / رقم الهاتف